Compumedics

Compumedics Investing Cash Flow

The Net Investing Cash Flow of Compumedics (CMP.AX) as of Nov 22, 2026 is -3.90 M AUD. In the previous year, Net Investing Cash Flow was -7.37 M AUD — a change of -47.07% (higher).

Investing Cash Flow

-3.90 MAUD

YoY

-47.07%

Last updated:

Net Investing Cash Flow of Compumedics is 2026 -3.90 M AUD. Net Investing Cash Flow of Compumedics was 2025 -7.37 M AUD. It decreases by -47.07% higher compared to the previous year.

The Compumedics Investing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Investing Cash Flow
Date
Investing Cash Flow
Jan 1, 2019
-4.29 M AUD
Jan 1, 2020
-4.23 M AUD
Jan 1, 2021
-1.55 M AUD
Jan 1, 2022
-2.99 M AUD
Jan 1, 2023
-4.41 M AUD
Jan 1, 2024
-2.99 M AUD
Jan 1, 2025
-7.37 M AUD
Jan 1, 2026
-3.90 M AUD
The Compumedics Investing Cash Flow history
YEARInvesting Cash FlowYoY
-3.90 MAUD-47.07%
-7.37 MAUD+146.87%
-2.99 MAUD-32.24%
-4.41 MAUD+47.67%
-2.99 MAUD+92.08%
-1.55 MAUD-63.29%
-4.23 MAUD-1.24%
-4.29 MAUD+111.76%
-2.02 MAUD+56.78%
-1.29 MAUD-16.11%
-1.54 MAUD+20.23%
-1.28 MAUD+82.86%
-700,000.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Compumedics Stock analysis

What does Compumedics do? Compumedics Ltd. generates revenue through the sale of medical equipment including sleep diagnostic systems, clinical EEG systems, brain monitoring systems, and ultrasonic blood-flow systems. The company's product portfolio features Somfit/Somfit Pro, Grael 4K PSG:EEG, Grael PSG, Somte PSG, Somte, Okti, and Siesta 802, which are distributed across geographic segments Americas, Australia, Asia Pacific, and Europe and the Middle East. CMP's neurology laboratory solutions support clinical epilepsy monitoring, electromyography diagnostics, and transcranial doppler sonography. Compumedics Neuroscan brand offers brain research technologies for electroencephalogram, ERPs, source localization, and functional neuro-imaging. The company serves healthcare providers and medical facilities requiring diagnostic and monitoring equipment. Its products target neurology, sleep medicine, and clinical research applications. CMP's solutions are marketed under the Compumedics Neuroscan brand for brain research technologies. The geographic segments drive sales with specific product offerings tailored to regional healthcare needs. Compumedics Neuroscan technologies provide electroencephalogram and functional neuro-imaging solutions for research and clinical use. The company's product range includes diagnostic systems for sleep disorders, epilepsy monitoring, and blood-flow analysis. CMP's technical service and support services complement the hardware sales, ensuring customer satisfaction and repeat business. Sales are conducted through direct channels within the Americas, Australia, Asia Pacific, and Europe and the Middle East segments. Compumedics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Compumedics stock

Net Investing Cash Flow of Compumedics is -3.90 M AUD in 2026.

Net Investing Cash Flow of Compumedics changed from -7.37 M AUD to -3.90 M AUD, representing a -47.07% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Investing Cash Flow Compumedics since 2006 – with annual values, charts, and detailed analysis.

Investing cash flow measures cash used for or generated from investment activities, including CapEx, acquisitions, and asset sales.

Net Investing Cash Flow's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Investing Cash Flow's Compumedics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Compumedics

All Key Metrics — Compumedics